Takeda Ventures, Inc. is the corporate venture arm of Takeda Pharmaceutical Company, a world-class pharmaceutical company and the largest one in Japan, supporting therapeutic innovation in the biopharmaceutical sector through early stage capital investment and the provision of access to the resources of a multinational pharmaceutical company. Read more at takedaventures.com
Panel Discussion: Life Science & Healthcare Investors
Matthew Foy, Partner, SR One (Chair)
Ilan Zipkin, PhD, Senior Investment Director, Takeda Ventures
Maina Bhaman, Director of Healthcare Investments, Imperial Innovations
Jeanne Bolger, VP Venture Investing, Johnson & Johnson Innovation- JJDC
Vishal Gulati, MD, Venture Partner, DFJ Esprit
Deborah Harland, PhD, MBA, Partner, SR One
Senior Investment Director at Takeda Ventures, Inc. + more
I have been involved in biotechnology and pharmaceutical venture capital since 2000. Previously I was a Partner at the institutional venture firms Prospect Venture Partners and MPM Capital, where I focused on investments in therapeutics companies as well as platform technologies. In addition to serving on the Board of several private and public biotechnology companies, I served as the CEO of Chimeros, Inc., a protein-based system for the development of multivalent biologic therapeutics.
Senior Director, External Innovation, Takeda Ventures + more
Currently based in Israel, I joined TVI in September 2014 as Senior Director for External Innovation with a primary focus on Israel and Europe. Since 1998, I have held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies.